Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
A patient with metastatic pancreatic cancer, ECOG performance status 2, and pre-existing neuropathy faces sequential treatment decisions. This interactive case examines tolerability, molecular findings, and safety counseling without implying that every detected alteration is actionable.
Medical Oncology November 11th 2026
Cancer Therapy Advisor
In DeLLphi-305, median overall survival was 21.1 months with tarlatamab plus durvalumab versus 12.7 months with durvalumab alone after first-line chemoimmunotherapy. Cytokine release syndrome occurred in approximately half of patients receiving the combination.
Oncology News Central (ONC)
In SAFFRON, median overall survival reached 17.8 months with dual EGFR/MET inhibition versus 12.9 months with chemotherapy. Results apply to patients with MET overexpression and/or amplification after osimertinib progression, not all EGFR-mutated NSCLC.
Clinical Advances in Hematology & Oncology
Prior immunotherapy exposure, recurrence timing, and toxicity shape treatment choices in clear cell renal cell carcinoma. An expert review examines sequencing across adjuvant and metastatic settings, while identifying gaps in prospective evidence after adjuvant treatment.
Specialty Pharmacy Continuum
Accreditors described new programs for artificial intelligence and immunoglobulin services, revised oncology dispensing materials, and more frequent DMEPOS surveys, with differing eligibility, payer recognition, and compliance implications across specialty pharmacy settings.
Clinical Pharmacology November 3rd 2026
Older adults with advanced or metastatic urothelial carcinoma treated with enfortumab vedotin experienced substantially higher rates of severe toxicity and treatment discontinuation than younger patients, while survival outcomes appeared similar across age groups.
Medical Oncology October 21st 2026